Telomir Pharmaceuticals, Inc. (TELO)
- GlobeNewswire
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support New to The Street televised business show will feature Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) ("Company"), a pre-clinical stage pharmaceutical company, focused on its TELOMIR-1 drug that could reverse age-related common diseases - https://telomirpharma.com/ & https://newtothestreet.com/ NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Wor
- GlobeNewswire
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging Demonstrated a 40% increase in telomerase activity and lengthened telomeres in vitro in human cells Provided pre-clinical endpoints to determine “anti-aging” and “age-reversal” effects in dogs Outlined timeline for initiating human investigational new drug (IND) trials for osteoarthritis, along with animal IND
- GlobeNewswire
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase New York Times article supports belief that telomere shortening reduces longevity BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as t
